Functional Rating Scale 2.0 (FuRST 2.0): A patient-reported outcome measure of function for Huntington’s disease

BackgroundCurrent functional rating scales are not sensitive to the earliest functional changes in Huntington's disease (HD).ObjectiveThe Functional Rating Scale 2.0 (FuRST 2.0) is a patient-reported outcome (PRO) measure designed to be sensitive to the initial functional changes in HD, specifically stage 2 and mild stage 3, as defined by the Huntington's Disease Integrated Staging System (HD-ISS).MethodsWe followed standard assessment development methodology to create a PRO. Study 1 consisted of a Delphi panel which analyzed data from focus groups comprised of people with HD and companions from 6 countries. This was followed by four rounds of cognitive interviews through which we evaluated respondents' comprehension of the instructions, understanding of question and response options, and comfort with the material. Informal advice from a regulatory agency was garnered throughout the process.ResultsConcerns from the target population and regulators regarding instructions, questions, response options, and comfort with the material were addressed through modifications to the scale's wording and format.ConclusionsWe developed the FuRST 2.0 official working document (OWD), the penultimate version of the scale, using focus groups, a Delphi panel, iterative rounds of cognitive interviewing, and informal regulatory advice. Its psychometric properties are being evaluated in the FOCUS-HD validation studies from which the final version of the scale will be derived. The FuRST 2.0 OWD is available for use.

Authors

Institutions

Publication Details

Journal
Journal of Huntington s Disease
Published
2025-04-15
DOI
https://doi.org/10.1177/18796397251323549
Citations
5
Primary Topic
Genetic Neurodegenerative Diseases
Type
article
Field-Weighted Citation Impact
4.55

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Functional Rating Scale 2.0 (FuRST 2.0): A patient-reported outcome measure of function for Huntington’s disease

Cristina Sampaio, Jatin G. Vaidya, Rebecca Fuller, Cheryl Fitzer‐Attas et al.
5 citations
Journal of Huntington s Disease
Genetic Neurodegenerative Diseases
4.55
article

Functional Rating Scale 2.0 (FuRST 2.0): A patient-reported outcome measure of function for Huntington’s disease

Cristina Sampaio, Jatin G. Vaidya, Rebecca Fuller, Cheryl Fitzer‐Attas, Swati Sathe, Nancy R. LaPelle, Peter Feigenbaum, Glenn T. Stebbins, Neha Sinha, P S Dalal, Matthew W. Roché
article en
5 citations

Abstract

BackgroundCurrent functional rating scales are not sensitive to the earliest functional changes in Huntington's disease (HD).ObjectiveThe Functional Rating Scale 2.0 (FuRST 2.0) is a patient-reported outcome (PRO) measure designed to be sensitive to the initial functional changes in HD, specifically stage 2 and mild stage 3, as defined by the Huntington's Disease Integrated Staging System (HD-ISS).MethodsWe followed standard assessment development methodology to create a PRO. Study 1 consisted of a Delphi panel which analyzed data from focus groups comprised of people with HD and companions from 6 countries. This was followed by four rounds of cognitive interviews through which we evaluated respondents' comprehension of the instructions, understanding of question and response options, and comfort with the material. Informal advice from a regulatory agency was garnered throughout the process.ResultsConcerns from the target population and regulators regarding instructions, questions, response options, and comfort with the material were addressed through modifications to the scale's wording and format.ConclusionsWe developed the FuRST 2.0 official working document (OWD), the penultimate version of the scale, using focus groups, a Delphi panel, iterative rounds of cognitive interviewing, and informal regulatory advice. Its psychometric properties are being evaluated in the FOCUS-HD validation studies from which the final version of the scale will be derived. The FuRST 2.0 OWD is available for use.

Journal of Huntington s DiseaseVol. 14(2)
University of Iowa (US), Rush University Medical Center (US), CHDI Foundation (US)
CHDI Foundation
Partnerships for the goals
Openalex Percentile: Top 5%
Genetic Neurodegenerative Diseases
4.55
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.